AR075951A1 - Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek - Google Patents
Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mekInfo
- Publication number
- AR075951A1 AR075951A1 ARP100100964A ARP100100964A AR075951A1 AR 075951 A1 AR075951 A1 AR 075951A1 AR P100100964 A ARP100100964 A AR P100100964A AR P100100964 A ARP100100964 A AR P100100964A AR 075951 A1 AR075951 A1 AR 075951A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydroxy
- independently selected
- alkenyl
- halogen
- Prior art date
Links
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 2
- -1 phenylamino dihydropyridyl Chemical group 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 150000001412 amines Chemical class 0.000 abstract 4
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- XSJZFXKWCCMFKJ-UHFFFAOYSA-N O=S(=O)NC1=CC=CNC1NC1=CC=CC=C1 Chemical class O=S(=O)NC1=CC=CNC1NC1=CC=CC=C1 XSJZFXKWCCMFKJ-UHFFFAOYSA-N 0.000 abstract 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
N-(orto fenilamino dihidropiridil)sulfonamidas y N-(orto fenilamino dihidropiridil), N'-alquilsulfamidas que son inhibidores de MEK y de utilidad en el tratamiento de cáncer y otras enfermedades hiperproliferativas. Reivindicacion 1: Un compuesto caracterizado porque es de formula 1, o una sal, solvato, polimorfo, éster, tautomero o prodroga farmacéuticamente aceptable del mismo donde B es H, alquilo C1-6 o alquenilo C26; donde dicho alquilo C1-6 está opcionalmente sustituido con uno o dos grupos seleccionados en forma independiente entre hidroxi, alcoxi, oxi, amina y amina sustituida; A y A' son en forma independiente entre sí H, alquilo C1-6, o alquenilo C2-6; donde cada alquilo C1-6 está opcionalmente sustituido con uno o dos grupos seleccionados en forma independiente entre hidroxi, alcoxi, oxi, amina y amina sustituida; o A y A' junto con el átomo de carbono al cual se encuentran unidos, forman un grupo ciclopropilo, ciclobutilo, o ciclopentilo, donde cada grupo ciclopropilo, ciclobutilo, o ciclopentilo está opcionalmente sustituido con uno o dos grupos seleccionados en forma independiente entre metilo, hidroxi, y halogeno; X e Y son en forma independiente entre sí halogeno, metilo, SCH3 o trifluorometilo; R1 es H, alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, cicloalquenilo C5-6 o alquinilo C2-6; donde cada grupo alquilo, cicloalquilo, alquenilo, cicloalquenilo o alquinilo está opcionalmente sustituido con 1-3 sustituyentes seleccionados en forma independiente entre halogeno, hidroxi, alquilo C1-4, alcoxi C1-4, ciano, cianometilo, nitro, azido, trifluorometilo difluorometoxi y fenilo, y uno o dos átomos de carbono del anillo de dichos grupos cicloalquilo C3-6 se reemplazan opcionalmente en forma independiente por O, N, o S; o R1 es un grupo heterocíclico de 5 o 6 átomos, que puede ser saturado, insaturado, o aromático, que contiene 1-5 heteroátomos seleccionados en forma independiente entre O, N, y S, donde el grupo heterocíclico está opcionalmente sustituido con 1-3 sustituyentes seleccionados en forma independiente entre halogeno, hidroxi, alquilo C1-4, alcoxi C1-4, ciano, cianometilo, nitro, azido, trifluorometil difluorometoxi y fenilo; y R2 es H, halogeno, hidroxi, azido, ciano, cianometilo, alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, cicloalquenilo C5-6 o alquinilo C2-6, donde cada grupo alquilo, cicloalquilo, alquenilo, cicloalquenilo o alquinilo está opcionalmente sustituido con 1-3 sustituyentes seleccionados en forma independiente entre halogeno, hidroxi, alcoxi C1-4, ciano, cianometilo, nitro, azido, trifluorometilo y fenilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16431909P | 2009-03-27 | 2009-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075951A1 true AR075951A1 (es) | 2011-05-04 |
Family
ID=42112300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100964A AR075951A1 (es) | 2009-03-27 | 2010-03-26 | Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8673919B2 (es) |
| EP (1) | EP2411366B8 (es) |
| JP (1) | JP5844727B2 (es) |
| CN (2) | CN106478496A (es) |
| AR (1) | AR075951A1 (es) |
| CA (1) | CA2756566A1 (es) |
| ES (1) | ES2543608T3 (es) |
| WO (1) | WO2010108652A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3034994A1 (en) | 2008-06-03 | 2009-12-10 | Intermune, Inc. | Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CA2890238A1 (en) | 2012-11-02 | 2014-05-08 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
| FR3032496B1 (fr) | 2015-02-10 | 2017-08-18 | Monestrol Georges De | Dispositif pour le blocage d'un premier tube exterieur et d'un deuxieme tube interieur montes telescopiques entre eux. |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| IL299206A (en) * | 2020-06-23 | 2023-02-01 | Chemocentryx Inc | Methods for treating cancer using heteroaryl-biphenyl amide derivatives |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| JP2024521788A (ja) | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス， インコーポレイテッド | 併用療法 |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| JPH06135934A (ja) * | 1991-12-27 | 1994-05-17 | Ishihara Sangyo Kaisha Ltd | ピリジン誘導体又はその塩を含有するホスホリパーゼ▲ａ２▼阻害剤、抗炎症剤又は抗膵炎剤 |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| US5861510A (en) | 1995-04-20 | 1999-01-19 | Pfizer Inc | Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| BR9710381A (pt) | 1996-07-18 | 1999-08-17 | Pfizer | Inibidores de metaloproteases de matriz - base de fosfinato |
| CN1228083A (zh) | 1996-08-23 | 1999-09-08 | 美国辉瑞有限公司 | 芳基磺酰氨基异羟肟酸衍生物 |
| WO1998030566A1 (en) | 1997-01-06 | 1998-07-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| TR199901849T2 (xx) | 1997-02-03 | 2000-02-21 | Pfizer Products Inc. | Arils�lfonilamino hidroksamik asit t�revleri. |
| CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| EA002546B1 (ru) | 1997-02-11 | 2002-06-27 | Пфайзер Инк. | Производные арилсульфонилгидроксамовой кислоты |
| US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| EP1337524A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituted quinolines as antitumor agents |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| AU2004293018B2 (en) * | 2003-11-19 | 2010-02-18 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| ES2378760T3 (es) * | 2005-05-18 | 2012-04-17 | Array Biopharma, Inc. | Inhibidores heterocíclicos de MEK y métodos de uso de los mismos |
| ES2481402T3 (es) * | 2005-07-21 | 2014-07-30 | Ardea Biosciences, Inc. | Inhibidores de N-(arilamino)sulfonamida de MEK |
| JP5269762B2 (ja) | 2006-04-18 | 2013-08-21 | アーディア・バイオサイエンシーズ・インコーポレイテッド | Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド |
| CN102134218A (zh) * | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
-
2010
- 2010-03-23 CN CN201610768696.1A patent/CN106478496A/zh active Pending
- 2010-03-23 US US13/259,239 patent/US8673919B2/en not_active Expired - Fee Related
- 2010-03-23 EP EP10711012.4A patent/EP2411366B8/en not_active Not-in-force
- 2010-03-23 WO PCT/EP2010/001808 patent/WO2010108652A1/en not_active Ceased
- 2010-03-23 CN CN2010800227265A patent/CN102448938A/zh active Pending
- 2010-03-23 ES ES10711012.4T patent/ES2543608T3/es active Active
- 2010-03-23 CA CA2756566A patent/CA2756566A1/en not_active Abandoned
- 2010-03-23 JP JP2012501180A patent/JP5844727B2/ja not_active Expired - Fee Related
- 2010-03-26 AR ARP100100964A patent/AR075951A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5844727B2 (ja) | 2016-01-20 |
| US20120107307A1 (en) | 2012-05-03 |
| CN102448938A (zh) | 2012-05-09 |
| EP2411366A1 (en) | 2012-02-01 |
| EP2411366B8 (en) | 2015-07-15 |
| US8673919B2 (en) | 2014-03-18 |
| EP2411366B1 (en) | 2015-05-20 |
| CA2756566A1 (en) | 2010-09-30 |
| ES2543608T3 (es) | 2015-08-20 |
| JP2012521968A (ja) | 2012-09-20 |
| CN106478496A (zh) | 2017-03-08 |
| WO2010108652A1 (en) | 2010-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075951A1 (es) | Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek | |
| PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| AR066043A1 (es) | Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1) | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| AR075635A1 (es) | N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos | |
| EA201591000A1 (ru) | Пирролобензодиазепины | |
| AR098912A1 (es) | Inhibidores de syk | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| ES2570756T3 (es) | Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR060489A1 (es) | Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol | |
| PE20131165A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR101177A1 (es) | Inhibidores de la syk | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| ECSP13013038A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |